| VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20589168 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
Aurora kinases are key regulators of cell mitosis and have been implicated in the process of tumorigenesis. In recent years, the Aurora kinases have attracted much interest as promising targets for cancer treatment. Here we report on the roles of Aurora A and Aurora B kinases in clear cell renal cell carcinoma (ccRCC). Using genomewide expression array analysis of 174 patient samples of ccRCC, we found that expression levels of Aurora A and B were significantly elevated in ccRCC compared to normal kidney samples. High expression levels of Aurora A and Aurora B were significantly associated with advanced tumor stage and poor patient survival. Inhibition of Aurora kinase activity with the drug VX680 (also referred to as MK-0457) inhibited ccRCC cell growth in vitro and led to ccRCC cell accumulation in the G2/M phase and apoptosis. Growth of ccRCC xenograft tumors was also inhibited by VX680 treatment, accompanied by a reduction of tumor microvessel density. Analysis of endothelial cell lines demonstrated that VX680 inhibits endothelial cell growth with effects similar to that seen in ccRCC cells. Our findings suggest that VX680 inhibits the growth of ccRCC tumors by targeting the proliferation of both ccRCC tumor cells and tumor-associated endothelial cells. Aurora kinases and their downstream cell cycle proteins have an important role in ccRCC and may be potent prognostic markers and therapy targets for this disease. |
| | |
Authors:
|
Yan Li; Zhong-Fa Zhang; Jindong Chen; Dan Huang; Yan Ding; Min-Han Tan; Chao-Nan Qian; James H Resau; Hyung Kim; Bin Tean Teh |
Related Documents
:
|
16082428 - Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer t... 19917848 - Pancreatic endocrine tumors: expression profiling evidences a role for akt-mtor pathway. 16897758 - P-akt expression distinguishes two types of malignant rhabdoid tumors. 19938898 - Small-molecule inhibitors of the human epidermal receptor family. 8823768 - Pathology of cerebral metastases. 10956408 - Prognostic significance of the ca(2+) binding protein s100a2 in laryngeal squamous-cell... |
Publication Detail:
|
Type: Journal Article Date: 2010-05-20 |
Journal Detail:
|
Title: American journal of translational research Volume: 2 ISSN: 1943-8141 ISO Abbreviation: Am J Transl Res Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-06-30 Completed Date: 2010-08-12 Revised Date: 2010-09-28 |
Medline Journal Info:
|
Nlm Unique ID: 101493030 Medline TA: Am J Transl Res Country: United States |
Other Details:
|
Languages: eng Pagination: 296-308 Citation Subset: - |
Affiliation:
|
Laboratory of Cancer Genetics, Laboratory of Analytical, Cellular, and Molecular Microscopy, Laboratory of Microarray Technology, Van Andel Research Institute, 333 Bostwick Ave N.E., Grand Rapids, Michigan 49503, USA; Departmentof Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union MedicalCollege, 1 Xian Nong Tan Street, Beijing, 100050, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bone marrow derived stem cells in regenerative medicine as Advanced Therapy Medicinal Products.
Next Document: Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.